After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular way US IPOs scheduled for the first week of November, though it is...read more
Seven IPOs and 10 SPACs went public this past week. The IPO pipeline remained active, with 11 IPOs and 22 SPACs submitting initial filings. Phase 2 biotech Kronos Bio (KRON) priced above the range to raise $250 million at a $1.1 billion...read more
Kronos Bio, a Phase 2 biotech developing kinase inhibitors for leukemia and solid tumors, raised $250 million by offering 13.2 million shares at $19, above the range of $16 to $18. The company originally planned to offer 10.3 million shares at the same range...read more
Kronos Bio, a Phase 2 biotech developing kinase inhibitors for leukemia and solid tumors, raised the proposed deal size for its upcoming IPO on Thursday. The San Mateo, CA-based company now plans to raise $224 million by offering 13.2 million shares at a...read more
US IPO Week Ahead: Hot IPO market takes a break for election week
After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular way US IPOs scheduled for the first week of November, though it is...read more
US IPO Weekly Recap: Healthcare dominates a 7 IPO week
Seven IPOs and 10 SPACs went public this past week. The IPO pipeline remained active, with 11 IPOs and 22 SPACs submitting initial filings. Phase 2 biotech Kronos Bio (KRON) priced above the range to raise $250 million at a $1.1 billion...read more
Oncology biotech Kronos Bio prices IPO above the range at $19
Kronos Bio, a Phase 2 biotech developing kinase inhibitors for leukemia and solid tumors, raised $250 million by offering 13.2 million shares at $19, above the range of $16 to $18. The company originally planned to offer 10.3 million shares at the same range...read more
Oncology biotech Kronos Bio increases deal size by 28% ahead of $224 million IPO
Kronos Bio, a Phase 2 biotech developing kinase inhibitors for leukemia and solid tumors, raised the proposed deal size for its upcoming IPO on Thursday. The San Mateo, CA-based company now plans to raise $224 million by offering 13.2 million shares at a...read more